Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
"We envision PRP as a welcome addition to the treatment process, as a long term, metronomic therapy that minimizes threat of recurrence"
"We envision PRP as a welcome addition to the treatment process, as a long term, metronomic therapy that minimizes threat of recurrence"